MARKET

IMMU

IMMU

Immunomedics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

85.53
+0.19
+0.22%
After Hours: 85.72 +0.19 +0.22% 19:43 09/18 EDT
OPEN
85.70
PREV CLOSE
85.34
HIGH
85.78
LOW
85.26
VOLUME
9.25M
TURNOVER
--
52 WEEK HIGH
86.91
52 WEEK LOW
8.80
MARKET CAP
19.77B
P/E (TTM)
-49.6892
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile

Analyst Price Target

The average IMMU stock price target is 73.56 with a high estimate of 88.00 and a low estimate of 47.60.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About IMMU
Immunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. It has a pipeline of six clinical-stage product candidates. Its portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a payload of a chemotherapeutic directly to the tumor, while the managing overall toxic effects that are found with conventional administration of these chemotherapy agents. Its ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130). The Company also has a range of other product candidates that target solid tumors and hematologic malignancies, as well as other diseases, in various-stages of clinical and pre-clinical development.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Immunomedics, Inc. stock information, including NASDAQ:IMMU real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMMU stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IMMU stock methods without spending real money on the virtual paper trading platform.